Milestone Pharmaceuticals Q2 FY26 net loss widens 120.7% to $28.61 million

Milestone Pharmaceuticals posted a net loss of $28.61 million for the quarter ended June 30, 2026, worsening 120.7% year over year.

• Revenue turned to $559,000, driven by CARDAMYST product sales; no revenue was recorded a year earlier.
• Selling, general and administrative costs climbed 155.6% to $22.65 million, due to personnel, professional, and launch-related operational spending for CARDAMYST.
• Research and development expense edged down 4.4% to $3.51 million, while interest expense jumped 396.9% to $4.73 million.
• Cash and cash equivalents totaled $169.7 million at June 30, 2026; the company expects funding to cover at least 12 months.